Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection

Herein, we demonstrated the development and characterization of a dry powder inhaler (DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for the management of pulmonary or cerebral coagulopathy associated with COVID-19 infection. The formulations were prepared b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashid, Md Abdur, Muneer, Saiqa, Mendhi, Jayanti, Sabuj, Mohammad Zaidur Rahman, Alhamhoom, Yahya, Xiao, Yin, Wang, Tony, Izake, Emad L., Islam, Nazrul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463814/
https://www.ncbi.nlm.nih.gov/pubmed/34560207
http://dx.doi.org/10.1016/j.ijpharm.2021.121122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463814/
https://www.ncbi.nlm.nih.gov/pubmed/34560207
http://dx.doi.org/10.1016/j.ijpharm.2021.121122

Ejemplares similares